euro adhoc: november AG
other
november AG publishes results of
the financial year 2004
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
17.03.2005
Erlangen, March 17, 2005. In the past financial year, the Erlangen (Germany) based biotech company november AG (ISIN DE0006762909) was able to reach consolidated sales revenues of EUR 5.6 million thus exceeding the previous years level (EUR 4.4 million) by 26 %. The groups operating result (EBIT) amounted to EUR -4.2 million surpassing the previous years figure (EUR -4.4 million) by 5 %. At EUR -0.29, the earnings per share (IAS 33) also saw a significant improvement (PY: EUR -0.41, IAS 33).
One of the reasons for the positive business development of the year under review is the positioning of november AG as a holding: Since January 1, 2004, the former business units Product Security/Brand Protection and Diagnosis have operated as subsidiaries, identif GmbH and directif GmbH. The new corporate structure aims at enabling more flexible reactions to the needs of the specific market segments and customer wishes as well as simplifying entry into the november group for financial and strategic investors. New equity participations, subsequent orders from the pharmaceutical industry and partnerships with prominent industrial companies supported the positive business development of november AG in the financial year 2004.
The management board will give a detailed report on last years business development of november AG on the occasion of the press conference on annual results and analysts meeting, taking place in Frankfurt/Main on March 31, 2005. The new annual report will also be introduced on this occasion.
Annotation:
Journalists who would like to participate in the press conference on annual results taking place in Frankfurt/Main on March 31, 2005, are kindly requested to register with Ms. Andrea Steuer, Investor Relations / Public Relations.
november AG is an Erlangen (Germany) based listed biotech company (Frankfurt Stock Exchange Prime Standard, ISIN DE0006762909, SE symbol NBX) with, inter alia, a focus on development in the field of nanotechnology. Organized as a holding company, the group also includes the subsidiaries identif GmbH (product security & brand protection), directif GmbH (lab independent nucleic acid testing), and PEQLAB Biotechnologie GmbH (biotech R&D supplier). Since 2002, first brand protection products are available with pharma company Bristol-Myers Squibb (Germany) among the first customers. For diagnostics and based on a patented technology, directif GmbH develops the world's first fully integrated nucleic acid testing device which will provide fast and cost-efficient detection of pathogens on the genetic level even at the point of care. On a contractual basis, november will participate in the development of a novel immunotherapeutic approach to fight cancer through profit share options. This new therapy is being developed by responsif GmbH, the former therapeutic business unit of november AG whose management conducted a management buy-out in early 2003.
end of announcement euro adhoc 17.03.2005 09:55:59
Further inquiry note:
Andrea Steuer
Manager Investor Relations/Public Relations
Tel.: +49(0)9131-75088-868
E-Mail: steuer@november.de
Branche: Biotechnology
ISIN: DE0006762909
WKN: 676290
Index: CDAX, Technologie All Share, Prime All Share, Prime Standard
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Berliner Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade